Complete Filing Data
Autonomix Medical, Inc. reported Stockholders Equity of $644.0 thousand for FY2023.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Autonomix Medical, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income Loss | -$11.4M | -$15.4M | -$2.0M |
| Research And Development Expense | $4.7M | $2.2M | $745.0K |
| Operating Income Loss | -$11.6M | -$12.0M | -$2.0M |
| Operating Expenses | $11.6M | $12.0M | $2.0M |
| Nonoperating Income Expense | $178.0K | -$3.4M | $0.00 |
| Income Tax Expense Benefit | $0.00 | $0.00 | $0.00 |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$11.4M | -$15.4M | -$2.0M |
| General And Administrative Expense | $6.9M | $5.2M | $1.2M |
| Interest Expense Nonoperating | $176.0K | $79.0K | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Loss | -$3.3M | -$7.5M | -$3.3M | -$11.4M | -$2.7M | -$2.8M | -$2.7M | -$15.4M | -$3.1M | -$6.0M | -$865.0K | -$544.0K | -$448.0K | -$341.0K |
| Research And Development Expense | $1.7M | $2.4M | $1.6M | $1.0M | $1.2M | $954.0K | $687.0K | $471.0K | $368.0K | $199.0K | ||||
| Operating Income Loss | -$3.3M | -$7.5M | -$3.4M | -$2.7M | -$2.8M | -$2.8M | -$2.9M | -$5.8M | -$871.0K | -$544.0K | ||||
| Operating Expenses | $3.3M | $7.5M | $3.4M | $2.7M | $2.8M | $2.8M | $2.9M | $5.8M | $871.0K | $544.0K | ||||
| Nonoperating Income Expense | $82.0K | $83.0K | $84.0K | $35.0K | $29.0K | $54.0K | -$189.0K | -$220.0K | $6.0K | $0.00 | ||||
| Income Tax Expense Benefit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$3.3M | -$7.5M | -$3.3M | -$2.7M | -$2.8M | -$2.7M | -$3.1M | -$6.0M | -$865.0K | -$544.0K | ||||
| General And Administrative Expense | $1.6M | $5.2M | $1.8M | $1.7M | $1.7M | $1.8M | $2.2M | $793.0K | $503.0K | $345.0K | ||||
| Interest Expense Nonoperating | $0.00 | $0.00 | $0.00 | $45.0K | $43.0K | $41.0K | $33.0K | $0.00 | $0.00 |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Stockholders Equity | $644.0K | $2.0M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $865.0K | $2.0M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $7.7M | -$1.2M | ||
| Retained Earnings Accumulated Deficit | -$39.0M | -$23.5M | ||
| Property Plant And Equipment Net | $16.0K | $0.00 | ||
| Preferred Stock Value | $0.00 | $0.00 | ||
| Other Assets Current | $783.0K | $0.00 | ||
| Liabilities Current | $777.0K | $221.0K | ||
| Liabilities And Stockholders Equity | $9.4M | $865.0K | ||
| Liabilities | $1.8M | $221.0K | ||
| Common Stock Value | $1.0K | $12.0K | ||
| Assets Noncurrent | $16.0K | $0.00 | ||
| Assets Current | $9.4M | $865.0K | ||
| Assets | $9.4M | $865.0K | ||
| Accrued Liabilities Current | $285.0K | $48.0K | ||
| Accounts Payable Current | $492.0K | $173.0K | ||
| Cash And Cash Equivalents At Carrying Value | $8.6M | $865.0K | ||
| Liabilities Noncurrent | $0.00 | $1.0M | $0.00 | |
| Deferred Costs | $0.00 | |||
| Convertible Long Term Notes Payable | $0.00 | $1.0M | $0.00 | |
| Warrants Issued For Equity Costs | ||||
| Warrants Issued For Debt Issuance Costs | ||||
| Deferred Financing Costs Related To The Issuance Of Common Stock | ||||
| Stock And Warrants Issued During Period Value Common Stock And Warrants | $9.0M | |||
| Warrant Liability Markto Market |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $8.6M | $6.4M | $7.0M | $8.1M | $9.7M | $3.0M | $5.3M | $7.6M | -$5.6M | -$2.9M | $2.6M | $626.0K | $1.2M | $1.6M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $9.9M | $7.5M | $8.6M | $9.1M | $11.8M | $5.2M | $6.8M | $8.6M | $2.1M | $2.9M | $865.0K | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$547.0K | $528.0K | -$1.9M | $7.7M | $2.1M | ||||||||||
| Retained Earnings Accumulated Deficit | -$64.4M | -$61.2M | -$53.7M | -$50.4M | -$47.2M | -$44.5M | -$41.7M | -$33.6M | |||||||
| Property Plant And Equipment Net | $20.0K | $16.0K | $19.0K | $21.0K | $20.0K | $17.0K | $19.0K | $14.0K | |||||||
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||
| Other Assets Current | $257.0K | $416.0K | $389.0K | $473.0K | $109.0K | $199.0K | $325.0K | $467.0K | |||||||
| Liabilities Current | $1.7M | $1.5M | $2.0M | $1.7M | $2.2M | $1.3M | $763.0K | $973.0K | |||||||
| Liabilities And Stockholders Equity | $10.2M | $7.9M | $9.0M | $9.8M | $12.0M | $5.4M | $7.1M | $1.8M | |||||||
| Liabilities | $1.7M | $1.5M | $2.0M | $1.7M | $2.2M | $2.3M | $1.8M | $7.4M | |||||||
| Common Stock Value | $11.0K | $6.0K | $4.0K | $2.0K | $2.0K | $1.0K | $19.0K | $14.0K | |||||||
| Assets Noncurrent | $20.0K | $39.0K | $19.0K | $197.0K | $20.0K | $17.0K | $19.0K | $124.0K | |||||||
| Assets Current | $10.2M | $7.9M | $9.0M | $9.6M | $11.9M | $5.4M | $7.1M | $1.7M | |||||||
| Assets | $10.2M | $7.9M | $9.0M | $9.8M | $12.0M | $5.4M | $7.1M | $1.8M | |||||||
| Accrued Liabilities Current | $936.0K | $645.0K | $1.2M | $1.0M | $881.0K | $683.0K | $476.0K | $310.0K | |||||||
| Accounts Payable Current | $714.0K | $842.0K | $815.0K | $676.0K | $232.0K | $574.0K | $287.0K | $663.0K | |||||||
| Cash And Cash Equivalents At Carrying Value | $9.9M | $7.5M | $8.6M | $9.1M | $11.8M | $5.2M | $6.8M | ||||||||
| Liabilities Noncurrent | $0.00 | $1.1M | $1.0M | $6.4M | |||||||||||
| Deferred Costs | $0.00 | $23.0K | $0.00 | $176.0K | |||||||||||
| Convertible Long Term Notes Payable | $0.00 | $1.1M | $1.0M | ||||||||||||
| Warrants Issued For Equity Costs | $479.0K | $0.00 | |||||||||||||
| Warrants Issued For Debt Issuance Costs | $0.00 | $577.0K | |||||||||||||
| Deferred Financing Costs Related To The Issuance Of Common Stock | -$176.0K | $0.00 | |||||||||||||
| Stock And Warrants Issued During Period Value Common Stock And Warrants | $9.0M | ||||||||||||||
| Warrant Liability Markto Market | $179.0K | $0.00 |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$8.3M | -$6.6M | -$1.9M |
| Share Based Compensation | $618.0K | $0.00 | |
| Payments To Acquire Property Plant And Equipment | $19.0K | $0.00 | |
| Net Cash Provided By Used In Investing Activities | -$19.0K | $0.00 | |
| Net Cash Provided By Used In Financing Activities | $14.4M | $675.0K | |
| Increase Decrease In Other Current Assets | $478.0K | -$9.0K | |
| Increase Decrease In Accrued Liabilities | $237.0K | $46.0K | |
| Depreciation Depletion And Amortization | $81.0K | $0.00 | |
| Payments Of Stock Issuance Costs | $200.0K | ||
| Increase Decrease In Accounts Payable Trade | $320.0K | $81.0K | |
| Proceeds From Convertible Debt | $2.0M | $0.00 | |
| Proceeds From Warrant Exercises | |||
| Payments Of Financing Costs | $1.1M | ||
| Payments For Initial Public Offering Issuance Costs | $1.3M | $0.00 | |
| Proceeds From Issuance Of Common Stock And Warrants | |||
| Proceeds From Issuance Initial Public Offering | $10.9M | $0.00 | |
| Proceeds From Issuance Of Common Stock | $2.8M | $675.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q2 2025 | Q1 2025 | Q2 2024 | Q1 2024 | Q2 2023 |
|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$2.6M | -$8.3M | -$1.9M | -$6.6M | -$661.0K |
| Share Based Compensation | $388.0K | $1.6M | $360.0K | $618.0K | $0.00 |
| Payments To Acquire Property Plant And Equipment | $0.00 | $14.0K | $5.0K | $19.0K | $0.00 |
| Net Cash Provided By Used In Investing Activities | $0.00 | -$14.0K | -$5.0K | -$19.0K | $0.00 |
| Net Cash Provided By Used In Financing Activities | $2.1M | $8.8M | $0.00 | $14.4M | $2.7M |
| Increase Decrease In Other Current Assets | -$84.0K | -$310.0K | -$458.0K | $478.0K | $25.0K |
| Increase Decrease In Accrued Liabilities | $118.0K | $746.0K | $191.0K | $237.0K | $20.0K |
| Depreciation Depletion And Amortization | $3.0K | $183.0K | $43.0K | $81.0K | $0.00 |
| Payments Of Stock Issuance Costs | $64.0K | $176.0K | $0.00 | $0.00 | $105.0K |
| Increase Decrease In Accounts Payable Trade | $140.0K | $184.0K | -$205.0K | $320.0K | $209.0K |
| Proceeds From Convertible Debt | $0.00 | $2.0M | |||
| Proceeds From Warrant Exercises | $1.0K | $0.00 | |||
| Payments Of Financing Costs | $1.1M | $0.00 | |||
| Payments For Initial Public Offering Issuance Costs | $0.00 | $1.3M | |||
| Proceeds From Issuance Of Common Stock And Warrants | $10.0M | $0.00 | |||
| Proceeds From Issuance Initial Public Offering | $0.00 | $10.9M | |||
| Proceeds From Issuance Of Common Stock | $0.00 | $2.8M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Authorized | 500.0M | 25.0M | |
| Weighted Average Number Of Shares Outstanding Basic | 1.8M | 1.0M | 12.0M |
| Preferred Stock Shares Authorized | 10.0M | 7.1M | |
| Earnings Per Share Basic | $-6.46 | $-14.82 | $-0.17 |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | |
| Preferred Stock Shares Issued | 0.00 | 0.00 | |
| Common Stock Shares Outstanding | 942.6K | 12.3M | |
| Common Stock Shares Issued | 942.6K | 12.3M | |
| Weighted Average Number Of Diluted Shares Outstanding | |||
| Earnings Per Share Diluted |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | 500.0M | |||
| Weighted Average Number Of Shares Outstanding Basic | 9.0M | 5.4M | 3.1M | 1.9M | 1.2M | 1.2M | 1.0M | 687.8K | 12.9M | 12.0M | |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | |||
| Earnings Per Share Basic | $-0.36 | $-1.38 | $-1.07 | $-1.46 | $-2.27 | $-2.20 | $-3.07 | $-8.78 | $-0.07 | $-0.05 | |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Common Stock Shares Outstanding | 11.4M | 6.2M | 4.0M | 2.5M | 2.5M | 1.2M | 19.2M | 14.4M | |||
| Common Stock Shares Issued | 11.4M | 6.2M | 4.0M | 2.5M | 2.5M | 1.2M | 19.2M | 14.4M | |||
| Weighted Average Number Of Diluted Shares Outstanding | 13.8M | 12.0M | |||||||||
| Earnings Per Share Diluted | $-0.23 | $-0.05 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $1.6M | $618.0K | |
| Investment Income Interest | $354.0K | $127.0K | $0.00 |
| Stock Issued During Period Value Warrants Exercised | $1.0K | $0.00 | |
| Stock Issued1 | $2.0K | $0.00 | |
| Stock Issued During Period Value New Issues | $103.0K | $2.8M | $675.0K |
| Additional Paid In Capital | $46.6M | $24.2M | |
| Gain Loss On Derivative Instruments Net Pretax | $0.00 | -$4.6M | $0.00 |
| Fair Value Adjustment Of Warrants | $0.00 | $3.4M | $0.00 |
| Issuance Of Stock And Warrants For Services Or Claims | |||
| Adjustments To Additional Paid In Capital Warrant Issued | $577.0K | $0.00 | |
| Ipo Proceeds Holdback Provision | $305.0K | $0.00 | |
| Class Of Warrant Or Right Fair Value Issued For Issuance Costs From Ipo | $225.0K | $0.00 | |
| Stock Issued During Period Value Conversion Of Convertible Securities | $1.2M | $500.0K | |
| Warrants Issued Fair Value Issued For Termination Agreement | $8.0M | ||
| Stock Issued During Period Value Initial Public Offering | $9.9M | ||
| Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | $0.00 | ||
| Warrant Expense Termination Agreement |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $2.0K | $138.0K | $388.0K | $418.0K | $445.0K | $360.0K | $212.0K | $151.0K | ||||
| Investment Income Interest | $82.0K | $83.0K | $84.0K | $80.0K | $72.0K | $95.0K | $23.0K | $19.0K | $6.0K | |||
| Stock Issued During Period Value Warrants Exercised | $4.0K | $2.3M | $0.00 | $1.0K | $0.00 | $0.00 | $0.00 | |||||
| Stock Issued1 | $0.00 | $39.0K | $4.0K | $2.0K | $0.00 | |||||||
| Stock Issued During Period Value New Issues | $860.0K | $473.0K | $1.9M | $101.0K | $2.8M | |||||||
| Additional Paid In Capital | $73.0M | $67.6M | $60.7M | $58.5M | $56.9M | $47.5M | $46.9M | $28.0M | ||||
| Gain Loss On Derivative Instruments Net Pretax | $0.00 | $0.00 | $0.00 | -$4.6M | $0.00 | -$4.6M | ||||||
| Fair Value Adjustment Of Warrants | $0.00 | $0.00 | $0.00 | $3.4M | $179.0K | $239.0K | ||||||
| Issuance Of Stock And Warrants For Services Or Claims | $101.0K | $0.00 | ||||||||||
| Adjustments To Additional Paid In Capital Warrant Issued | $4.5M | $230.0K | $346.0K | |||||||||
| Ipo Proceeds Holdback Provision | $0.00 | $305.0K | ||||||||||
| Class Of Warrant Or Right Fair Value Issued For Issuance Costs From Ipo | $0.00 | $225.0K | ||||||||||
| Stock Issued During Period Value Conversion Of Convertible Securities | ||||||||||||
| Warrants Issued Fair Value Issued For Termination Agreement | ||||||||||||
| Stock Issued During Period Value Initial Public Offering | ||||||||||||
| Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | ||||||||||||
| Warrant Expense Termination Agreement | $0.00 | $0.00 |
Most recent annual filing with the SEC: May 29, 2025
Data sourced from SEC EDGAR public filings as of August 5, 2026.